Management of dyslipidemia in adult solid organ transplant recipients
Tóm tắt
Từ khóa
Tài liệu tham khảo
Bostom, 2002, Prevention of post-transplant cardiovascular disease--report and recommendations of an ad hoc group, Am J Transplant, 2, 491, 10.1034/j.1600-6143.2002.20602.x
Agarwal, 2016, Post-transplant dyslipidemia: mechanisms, diagnosis and management, World J Transplant, 6, 125, 10.5500/wjt.v6.i1.125
Tsai, 2017, Cardiovascular disease risk in patients receiving organ transplantation: a national cohort study, Transpl Int, 30, 1161, 10.1111/tri.13010
Miller, 2002, Cardiovascular toxicities of immunosuppressive agents, Am J Transplant, 2, 807, 10.1034/j.1600-6143.2002.20902.x
Ross, 2006, Ten- and 20-year survivors of pediatric orthotopic heart transplantation, J Heart Lung Transplant, 25, 261, 10.1016/j.healun.2005.09.011
Taylor, 2005, Registry of the International Society for Heart and Lung Transplantation: twenty second official adult heart transplant report—2005, J Heart Lung Transplant, 24, 945, 10.1016/j.healun.2005.05.018
Costanzo, 1998, Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database, J Heart Lung Transplant, 17, 744
Roussel, 2008, Outcome of heart transplants 15 to 20 years ago: graft survival, post-transplant morbidity, and risk factors for mortality, J Heart Lung Transplant, 27, 486, 10.1016/j.healun.2008.01.019
Syeda, 2005, Transplant coronary artery disease: incidence, progression and interventional revascularization, Int J Cardiol, 104, 269, 10.1016/j.ijcard.2004.10.033
Haddad, 2005, Angiographic, pathologic, and clinical relationships in coronary artery disease in cardiac allografts, J Heart Lung Transplant, 24, 1218, 10.1016/j.healun.2004.08.016
Chih, 2016, Allograft vasculopathy: the Achilles’ heel of heart transplantation, J Am Coll Cardiol, 68, 80, 10.1016/j.jacc.2016.04.033
Wiggins, 2016, Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association, Circulation, 134, e468, 10.1161/CIR.0000000000000456
Jardine, 2011, Prevention of cardiovascular disease I adult recipients of kidney transplants, Lancet, 378, 1419, 10.1016/S0140-6736(11)61334-2
Montero, 2015, Immunosuppression and post-transplant hyperglycemia, Curr Diabetes Rev, 11, 144, 10.2174/1573399811666150331160846
Mathis, 2004, Drug-related dyslipidemia after renal transplantation, Am J Health Syst Pharm, 61, 565, 10.1093/ajhp/61.6.565
Miccoli, 2008, Insulin resistance and lipid disorders, Future Lipidol, 3, 651, 10.2217/17460875.3.6.651
Hricik, 1991, Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia, Am J Kidney Dis, 18, 353, 10.1016/S0272-6386(12)80095-3
Vathsala, 1989, Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients, Transplantation, 48, 37, 10.1097/00007890-198907000-00009
Azzi, 2013, Calcineurin inhibitors: 40 years later, can't live without …, J Immunol, 191, 5785, 10.4049/jimmunol.1390055
Kasiske, 1991, The adverse impact of cyclosporine on serum lipids in renal transplant recipients, Am J Kidney Dis, 17, 700, 10.1016/S0272-6386(12)80355-6
Ballantyne, 1989, Effects of cyclosporine therapy on plasma lipoprotein levels, JAMA, 262, 53, 10.1001/jama.1989.03430010065032
Claesson, 1998, Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients, Transplant Proc, 30, 1292, 10.1016/S0041-1345(98)00246-2
Friemann, 1998, Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus, Transplant Proc, 30, 1240, 10.1016/S0041-1345(98)00226-7
Jurewicz, 1999, Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report, Transplant Proc, 3, 64S, 10.1016/S0041-1345(99)00798-8
Vanrenterghem, 2000, Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection, Transplantation, 70, 1352, 10.1097/00007890-200011150-00015
Johnson, 2000, Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate after cadaveric kidney transplantation, Transplantation, 69, 834, 10.1097/00007890-200003150-00028
Venkiteswaran, 2001, Tacrolimus, cyclosporine and plasma lipoproteins in renal transplant recipients, Transpl Int, 14, 405, 10.1111/j.1432-2277.2001.tb00079.x
Ichimaru, 2001, Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus, Atherosclerosis, 158, 417, 10.1016/S0021-9150(01)00438-5
Flechner, 2002, Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine, Transplantation, 74, 1070, 10.1097/00007890-200210270-00002
Blum, 2002, Effects of sirolimus on lipids in renal allograft recipients: an analysis using Framingham risk model, Am J Transplant, 2, 551, 10.1034/j.1600-6143.2002.20610.x
Taylor, 1999, A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus, J Heart Lung Transplant, 18, 336, 10.1016/S1053-2498(98)00060-6
Kahan, 2000, Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group, Lancet, 356, 194, 10.1016/S0140-6736(00)02480-6
Tedesco Silva, 2003, Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty, Transplant Proc, 35, 177S, 10.1016/S0041-1345(03)00232-X
Gonwa, 2003, Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months, Transplantation, 75, 1213, 10.1097/01.TP.0000062837.99400.60
Chueh, 2003, Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis, Transplantation, 76, 375, 10.1097/01.TP.0000074310.40484.94
Ciancio, 2004, A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year, Transplantation, 77, 252, 10.1097/01.TP.0000101495.22734.07
Vitko, 2005, Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients, Am J Transplant, 5, 2521, 10.1111/j.1600-6143.2005.01063.x
Lorber, 2005, Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study, Transplantation, 80, 244, 10.1097/01.TP.0000164352.65613.24
Vitko, 2006, Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study, Am J Transplant, 6, 531, 10.1111/j.1600-6143.2005.01193.x
Trotter, 2001, Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus, Liver Transpl, 7, 401, 10.1053/jlts.2001.23916
Larson, 2006, Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus, Am J Transplant, 6, 514, 10.1111/j.1600-6143.2005.01177.x
Pirsch, 1997, A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation, Transplantation, 63, 977, 10.1097/00007890-199704150-00013
Hohage, 1997, Effects of cyclosporine A and FK 506 on lipid metabolism and fibrinogen in kidney transplant recipients, Clin Transplant, 11, 225
Satterthwaite, 1998, Incidence of new-onset hypercholesterolemia in renal transplant patients with FK506 or cyclosporine, Transplantation, 65, 446, 10.1097/00007890-199802150-00030
Jensik, 1998, Tacrolimus (FK506) in kidney transplantation: three-year survival results of the US multicenter, randomized comparative trial, Transplant Proc, 30, 1216, 10.1016/S0041-1345(98)00216-4
Raofi, 1999, A prospective randomized trial comparing the efficacy of tacrolimus versus cyclosporine in black recipients of primary cadaveric renal transplants, Am J Surg, 177, 299, 10.1016/S0002-9610(99)00042-2
Vela, 2000, Prospective study of lipid disorders in FK506-versus cyclosporine-treated renal transplant recipients, Transplant Proc, 32, 398, 10.1016/S0041-1345(99)00993-8
Boots, 2001, Single-center experience with tacrolimus versus cyclosporine-neoral in renal transplant recipients, Transpl Int, 14, 370, 10.1111/j.1432-2277.2001.tb00075.x
Ricoult, 2013, The multifaceted role of mTORC1 in the control of lipid metabolism, EMBO Rep, 14, 242, 10.1038/embor.2013.5
Morrisett, 2003, Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients, Transplant Proc, 25, 143S, 10.1016/S0041-1345(03)00233-1
Kasiske, 2008, Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients, Am J Transplant, 8, 1384, 10.1111/j.1600-6143.2008.02272.x
Aliabadi, 2008, Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation, Transplantation, 86, 1771, 10.1097/TP.0b013e3181910eb2
Raichlin, 2007, Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation, Circulation, 116, 2726, 10.1161/CIRCULATIONAHA.107.692996
Kreis, 2000, Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients, Transplantation, 69, 1252, 10.1097/00007890-200004150-00009
Vallakati, 2016, Impact of statin use after heart transplantation. A Meta-analysis, Circ Heart Fail, 9, e003265, 10.1161/CIRCHEARTFAILURE.116.003265
Mehra, 2004, Metaanalysis of statins and survival in de novo cardiac transplantation, Transplant Proc, 36, 1539, 10.1016/j.transproceed.2004.05.036
Costanzo, 2010, The international Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients, J Heart Lung Transplant, 29, 914, 10.1016/j.healun.2010.05.034
Harris, 2018, Optimal low-density lipoprotein concentration for cardiac allograft vasculopathy prevention, Clin Transplant, 32, e13248, 10.1111/ctr.13248
Holdaas, 2003, Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial, Lancet, 361, 2024, 10.1016/S0140-6736(03)13638-0
Holdaas, 2005, Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study, Am J Transplant, 5, 2929, 10.1111/j.1600-6143.2005.01105.x
Webster, 2015, Statins for kidney transplant recipients, Nephrology (Carlton), 20, 304, 10.1111/nep.12436
Kasiske, 2004, Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative, Am J Transplant, 4, 13, 10.1111/j.1600-6135.2004.0355.x
Wanner, 2014, KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient, Kidney Int, 85, 1303, 10.1038/ki.2014.31
Verleden, 2017, Statins in lung transplantation: a treatment option for every patient?, J Heart Lung Transplant, 36, 936, 10.1016/j.healun.2017.05.027
Hüsing, 2016, Lipids in liver transplant recipients, World J Gastroenterol, 22, 3315, 10.3748/wjg.v22.i12.3315
2002, Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143
Stone, 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2889, 10.1016/j.jacc.2013.11.002
Jacobson, 2015, National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report, J Clin Lipidol, 9, 129, 10.1016/j.jacl.2015.02.003
Jacobson, 2015, National lipid association recommendations for patient-centered management of dyslipidemia: part 2, J Clin Lipidol, 9, S1, 10.1016/j.jacl.2015.09.002
Jellinger, 2017, American associated of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease, Endocr Pract, 23, 1, 10.4158/EP171764.APPGL
Grundy, 2018, 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of cardiology/American heart association task force on clinical practice guidelines, J Am Coll Cardiol, 10.1016/j.jacc.2018.11.003
Riella, 2012, Dyslipidemia and its therapeutic challenges in renal transplantation, Am J Transplant, 12, 1975, 10.1111/j.1600-6143.2012.04084.x
Kupin, 1988, Complete replacement of methylprednisolone by azathioprine in cyclosporine-treated primary cadaveric renal transplant recipients, Transplantation, 45, 53, 10.1097/00007890-198801000-00012
Hricik, 1992, The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients, Transplantation, 54, 868, 10.1097/00007890-199211000-00019
Ratcliffe, 1996, Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression, Lancet, 348, 643, 10.1016/S0140-6736(96)02510-X
de Sévaux, 1998, A randomised, prospective study on the conversion from cyclosporine-prednisone to cyclosporine-azathioprine at 6 months after renal transplantation, Transpl Int, 11, S322, 10.1111/j.1432-2277.1998.tb01145.x
Ahsan, 1999, Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group, Transplantation, 68, 1865, 10.1097/00007890-199912270-00009
Mizuno, 2000, Trial of steroid withdrawal in renal transplant recipients with long-term--surviving allograft, Transplant Proc, 32, 1677, 10.1016/S0041-1345(00)01419-6
Matl, 2000, Withdrawal of steroids from triple-drug therapy in kidney transplant patients, Nephrol Dial Transplant, 15, 1041, 10.1093/ndt/15.7.1041
Lemieux, 2002, Effects of prednisone withdrawal on the new metabolic triad in cyclosporine-treated kidney transplant patients, Kidney Int, 62, 1839, 10.1046/j.1523-1755.2002.00611.x
Kato, 2006, Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients, Int Immunopharmacol, 6, 1984, 10.1016/j.intimp.2006.07.018
Pelletier, 2006, Prospective, randomized trial of steroid withdrawal in kidney recipients treated with mycophenolate mofetil and cyclosporine, Clin Transplant, 20, 10, 10.1111/j.1399-0012.2005.00430.x
McCune, 1998, Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study, Transplantation, 65, 87, 10.1097/00007890-199801150-00017
Busque, 1998, Conversion from Neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis, Transplant Proc, 30, 1247, 10.1016/S0041-1345(98)00229-2
Thorp, 2000, The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol, Transplantation, 69, 1218, 10.1097/00007890-200003270-00029
Kohnle, 2000, Conversion from cyclosporine A to tacrolimus after kidney transplantation due to hyperlipidemia, Transpl Int, 13, S345, 10.1111/j.1432-2277.2000.tb02057.x
Manzarbeitia, 2001, Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients, Liver Transpl, 7, 93, 10.1053/jlts.2001.21289
Ligtenberg, 2001, Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus, J Am Soc Nephrol, 12, 368, 10.1681/ASN.V122368
Artz, 2002, Randomized conversion from cyclosporine to tacrolimus in renal transplant patients: improved lipid profile and unchanged plasma homocysteine levels, Transplant Proc, 34, 1793, 10.1016/S0041-1345(02)03080-4
Colak, 2002, Effect of conversion from cyclosporine to tacrolimus on lipid profiles in renal transplant recipients, Transplant Proc, 34, 2081, 10.1016/S0041-1345(02)02859-2
Baid-Agrawal, 2004, Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients, Transplantation, 77, 1199, 10.1097/01.TP.0000119349.70491.F9
Marcen, 2006, Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study, Transplant Proc, 38, 2427, 10.1016/j.transproceed.2006.08.070
Seymen, 2009, Effects of cyclosporine-tacrolimus switching in posttransplantation hyperlipidemia on high-density lipoprotein 2/3, lipoprotein a1/b, and other lipid parameters, Transplant Proc, 41, 4181, 10.1016/j.transproceed.2009.09.069
Beckebaum, 2009, Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients, Aliment Pharmacol Ther, 30, 834, 10.1111/j.1365-2036.2009.04099.x
Kellick, 2014, A clinician’s guide to statin drug-drug interactions, J Clin Lipidol, 8, S30, 10.1016/j.jacl.2014.02.010
Norman, 1988, Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin, N Engl J Med, 318, 46, 10.1056/NEJM198801073180110
Lemahieu, 2005, Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus, Am J Transplant, 5, 2236, 10.1111/j.1600-6143.2005.01005.x
Skalicka, 2009, Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin, J Heart Lung Transplant, 28, 598, 10.1016/j.healun.2009.03.014
Mück, 1999, Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients, Clin Pharmacol Ther, 65, 251, 10.1016/S0009-9236(99)70104-9
Renders, 2003, Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients, Br J Clin Pharmacol, 56, 214, 10.1046/j.1365-2125.2003.01870.x
Samman, 2005, Safety and efficacy of rosuvastatin therapy for the prevention of hyperlipidemia in adult cardiac transplant recipients, J Heart Lung Transplant, 24, 1008, 10.1016/j.healun.2004.07.016
Sharif, 2009, The effect of rosuvastatin on insulin sensitivity and pancreatic beta-cell function in nondiabetic renal transplant recipients, Am J Transplant, 9, 1439, 10.1111/j.1600-6143.2009.02644.x
Robertson, 2014, More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients, Transplantation, 97, 1266, 10.1097/01.TP.0000443225.66960.7e
Celik, 2008, Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients, Transplantation, 86, 245, 10.1097/TP.0b013e318177281e
Kotanko, 2002, Rhabdomyolysis and acute renal graft impairment in a patient treated with simvastatin, tacrolimus, and fusidic acid, Nephron, 90, 234, 10.1159/000049053
Dopazo, 2009, Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with rapamycin plus tacrolimus in liver transplant patient, Transplant Proc, 41, 1021, 10.1016/j.transproceed.2009.02.019
2007
Bergman, 2006, Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects, J Clin Pharmacol, 46, 321, 10.1177/0091270005284851
Bergman, 2006, Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients, J Clin Pharmacol, 46, 328, 10.1177/0091270005284852
Koshman, 2005, Supratherapeutic response to ezetimibe administered with cyclosporine, Ann Pharmacother, 39, 1561, 10.1345/aph.1G015
Makkar, 2013, An observational study of ezetimibe in cardiac transplant recipients receiving calcineurin inhibitors, Ann Pharmacother, 47, 1457, 10.1177/1060028013504077
Almutairi, 2009, Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia, Liver Transpl, 15, 504, 10.1002/lt.21710
Quarta, 2008, Safety and efficacy of ezetimibe with low doses of simvastatin in heart transplant recipients, J Heart Lung Transplant, 27, 685, 10.1016/j.healun.2008.02.014
Lopez, 2008, Treatment with ezetimibe in kidney transplant recipients with uncontrolled dyslipidemia, Transplant Proc, 40, 2925, 10.1016/j.transproceed.2008.09.046
Crespo-Leiro, 2008, The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation, Transplant Proc, 40, 3060, 10.1016/j.transproceed.2008.09.007
Shaw, 2009, The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin, Transplantation, 87, 771, 10.1097/TP.0b013e318198d7d0
Puthenparumpil, 2005, Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population, Transplant Proc, 37, 1033, 10.1016/j.transproceed.2004.12.231
Langone, 2006, Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors, Transplantation, 81, 804, 10.1097/01.tp.0000203167.77570.11
Kohnle, 2006, Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation, Am J Transplant, 6, 205, 10.1111/j.1600-6143.2005.01132.x
Buchanan, 2006, A retrospective analysis of ezetimibe treatment in renal transplant recipients, Am J Transplant, 6, 770, 10.1111/j.1600-6143.2006.01263.x
Patel, 2007, Treatment of hypercholesterolemia with ezetimibe in cardiac transplant recipients, J Heart Lung Transplant, 26, 281, 10.1016/j.healun.2007.01.008
Moro, 2007, Ezetimibe in heart transplantation: initial experience, Transplant Proc, 39, 2389, 10.1016/j.transproceed.2007.06.043
Chuang, 2007, Ezetimibe reduces low-density lipoprotein cholesterol (LDL-C) in renal transplant patients resistant to HMG-CoA reductase inhibitors, Am J Ther, 14, 438, 10.1097/01.mjt.0000209693.83065.a6
Türk, 2008, Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study, Nephrol Dial Transplant, 23, 369, 10.1093/ndt/gfm620
Konstandin, 2008, Ezetimibe effectively lowers LDL-cholesterol in cardiac allograft recipients on stable statin therapy, Clin Transplant, 22, 639, 10.1111/j.1399-0012.2008.00838.x
Guisado Rasco, 2008, Safety and efficacy of ezetimibe in a sample of cardiac transplant patients, Transplant Proc, 40, 3058, 10.1016/j.transproceed.2008.09.048
Rodriguez-Ferrero, 2008, Safety and efficacy of ezetimibe in a sample of cardiac transplant patients, Transplant Proc, 40, 3492
Le, 2009, Impact of ezetimibe on cholesterol subfractions in dyslipidemic cardiac transplant recipients receiving statin therapy, Clin Transplant, 23, 249, 10.1111/j.1399-0012.2008.00920.x
Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N Engl J Med, 372, 2387, 10.1056/NEJMoa1410489
Bagdade, 1979, Effects of clofibrate on plasma lipids and high-density lipoprotein levels in renal allograft recipients, Clin Nephrol, 12, 83
Fuhrer, 1993, Impact of time-interval after transplantation and therapy with fibrates on serum cholesterol levels in renal transplant patients, Clin Nephrol, 39, 265
Peters, 1993, Treatment of hyperlipidemia in heart transplant recipients with gemfibrozil +/- lovastatin, Am J Cardiol, 71, 1485, 10.1016/0002-9149(93)90624-L
Boissonnat, 1994, The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients, Transplantation, 58, 245, 10.1097/00007890-199405820-00018
Chan, 1994, Hyperlipidemia after renal transplantation: treatment with gemfibrozil, Nephron, 67, 317, 10.1159/000187986
Perez-Jimenez, 1995, Comparison of lovastatin and bezafibrate on lipoprotein(a) plasma levels in cardiac transplant recipients, Am J Cardiol, 75, 648, 10.1016/S0002-9149(99)80642-0
Bastani, 1995, Post-transplant hyperlipidemia: risk factors and response to dietary modification and gemfibrozil therapy, Clin Transplant, 9, 340
Jespersen, 1995, Bezafibrate induced reduction of renal function in a renal transplant recipient, Nephrol Dial Transplant, 10, 702
Fehrman-Ekholm, 1996, Decreased cyclosporine levels during gemfibrozil treatment of hyperlipidemia after kidney transplantation, Nephron, 72, 483, 10.1159/000188918
Hanes, 1997, A crossover comparison of the efficacy and safety of lovastatin and gemfibrozil in the treatment of hyperlipidemic organ transplant recipients, Am J Ther, 4, 85, 10.1097/00045391-199702000-00006
Zambrana, 1998, Bezafibrate and lovastatin decrease the oxidizability of low-density lipoproteins in heart transplant recipients with hyperlipidemia, J Heart Lung Transplant, 17, 1213
Vergoulas, 2000, Combined treatment of hypercholesterolemia of renal transplant allograft recipients with fluvastatin and gemfibrozil, Transpl Int, 13, S64, 10.1111/j.1432-2277.2000.tb02118.x
Angeles, 2004, Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity, Am J Kidney Dis, 44, 543, 10.1016/S0272-6386(04)00832-7
Mir, 2015, Pharmacokinetic interaction involving fenofibrate and everolimus, Ann Oncol, 26, 248, 10.1093/annonc/mdu492
Tobert, 1988, Efficacy and long-term adverse effect pattern of lovastatin, Am J Cardiol, 62, 28J, 10.1016/0002-9149(88)90004-5
Ginsberg, 2010, Effects of combination lipid therapy in type 2 diabetes mellitus, N Engl J Med, 362, 1563, 10.1056/NEJMoa1001282
Page, 2005, Drug therapy in the heart transplant recipient: part IV: drug-drug interactions, Circulation, 111, 203, 10.1161/01.CIR.0000151805.86933.35
2011
Jensen, 1995, Does cholestyramine interfere with cyclosporine absorption? A prospective study in renal transplant patients, ASAIO J, 41, M704, 10.1097/00002480-199507000-00102
Lal, 1995, Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial, Am J Kidney Dis, 25, 616, 10.1016/0272-6386(95)90133-7
Boden, 2011, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy, N Engl J Med, 365, 2255, 10.1056/NEJMoa1107579
Landray, 2014, Effects of extended-release niacin with laropiprant in high-risk patients, N Engl J Med, 37, 203
1975, Clofibrate and niacin in coronary heart disease, JAMA, 231, 360, 10.1001/jama.1975.03240160024021
Canner, 1986, Fifteen year mortality in coronary drug project patients: long-term benefit with niacin, J Am Coll Cardiol, 8, 1245, 10.1016/S0735-1097(86)80293-5
Lim, 2016, Fish oil for kidney transplant recipients, Cochrane Database Syst Rev, 8, CD005282
Shah, 2013, Second line options for hyperlipidemia management after cardiac transplantation, Cardiovasc Ther, 31, 138, 10.1111/j.1755-5922.2012.00315.x
Nakamura, 1998, Evaluation of ethyl icosapentate in the treatment of hypercholesterolemia in kidney transplant recipients, Transplant Proc, 30, 3047, 10.1016/S0041-1345(98)00924-5
Bhatt, 2018, Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia, N Engl J Med, 380, 11, 10.1056/NEJMoa1812792
Hirunpanich, 2006, Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates: in vitro and in vivo evidence using cyclosporin in rats, Drug Metab Dispos, 34, 305, 10.1124/dmd.105.007088
Busnach, 1998, Effect of n-3 polyunsaturated fatty acids on cyclosporine pharmacokinetics in kidney graft recipients: a randomized placebo-controlled study, J Nephrol, 11, 87
Gidding, 2015, The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association, Circulation, 132, 2167, 10.1161/CIR.0000000000000297
2016
Rosenson, 2018, The evolving future of PCSK9 inhibitors, J Am Coll Cardiol, 72, 314, 10.1016/j.jacc.2018.04.054
Sima, 2017, Sirolimus therapy is associated with elevation in circulating PCSK9 levels in cardiac transplant patients, J Cardiovasc Transl Res, 10, 9, 10.1007/s12265-016-9719-8
Sabatine, 2017, Evolocumab and clinical outcomes in patients with cardiovascular disease, N Engl J Med, 376, 1713, 10.1056/NEJMoa1615664